The CSL AGM was held today.
Mgmt not spending much airtime (as in, speaking time, text dedicated to the topic) on their very large acquisition (e.g., Vifor) is not a highly encouraging sign, and “challenges in the growth profile” aren’t necessarily music to the ears either.

The 3-5 year forecast recovery in margin for the core IVIG franchise likewise continues to hold investor enthusiasm back. Mgmt point to the below metrics, each one they will endeavor to optimise, to drive that longer run recovery.

As always, for any manufacturing process, volume is key, and with plasma collections back to normal utilisation rates are higher, which is pleasing to see.

But the headline is very similar as it is for almost every other business out there “tight labour markets and general inflation are making it hard to maintain margin”.
Now, management know their target audience in an AGM setting. The below is the sort of slide long-term holders love to see, and a reminder of what they’ve been able to accomplish over time. They’ve definitely got the track record on their side.

Overall, the stock has de-rated quite sharply (PE multiple much lower), but the long and variable margin recovery time, combined with acquisition uncertainty (“where to” for Vifor), is a difficult set of parameters to parse.
We own the stock at an underweight, in most of our direct equity portfolios, and are market weight in one other.
The business is largely performing fine, it’s still growing at an attractive rate, has an enormous R&D pipeline (as it always does, that Hemgenix is, I think, the most expensive drug therapy in the world at the moment)…

…and there just aren’t that many companies growing top-line revenues at 9% constant currency (13-17% NPATA forecast for FY24).
So, we continue to hold, in the proportions that we do (market or sub-market weight) in order to maintain/contribute towards the overall “Quality” factor of the portfolio (our investment preference is QGARP, Quality Growth at a Reasonable Price).
Important Information: This document has been prepared by Aequitas Investment Partners Pty Ltd ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of AIP FS Pty Ltd ABN 49 680 982 478 (Australian Financial Services Licensee no. 700016) and is for distribution within Australia to wholesale clients only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Aequitas is not authorised to provide tax (financial) advice and is not a registered tax agent. Investors should seek their own tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law. We recommend that you consult a registered tax agent or a tax specialist to confirm your taxation position.